Viral Vitalism

Medicine

Compounding

Compounding news, research, studies, and rapid health briefings. Visit Viral Vitalism for plain-language context, evidence boundaries, and related signals.

0 published articles3 rapid briefsBuilding this topic
Coverage is being assembled with research and source context before this hub is promoted publicly.

News cycle

Rapid Briefs

View all ->
Peptide RegulationDeveloping

FDA Is Reviewing Compounded Peptide-Clinic Favorites

FDA's July advisory meeting covers BPC-157, Semax, Epitalon-related substances, MOTS-c, TB-500, KPV, DSIP/emideltide, and other peptide-related bulk substances popular in longevity circles.

Why now

The FDA calendar puts several longevity-clinic peptide favorites into a formal public regulatory review window.

Overclaim risk
high
Primary source
Official
Published
Jul 5, 2026
Read brief ->
Longevity SafetyDeveloping

FDA Panel Will Review Popular Longevity Peptides Amid Safety and Evidence Concerns

FDA advisers will review whether several popular peptides should be allowed for certain pharmacy compounding uses, while FDA materials flag limited human evidence and potential safety or quality concerns.

Why now

The peptide gray market just got a real FDA spotlight: BPC-157, TB-500, MOTS-c, Semax, and Epitalon are heading into a public review.

Overclaim risk
high
Primary source
Official
Published
Jun 30, 2026
Read brief ->
Drug SafetyConfirmed

The Compounded GLP-1 Boom Is Becoming a Patient-Safety and Trust Crisis

The weight-loss drug boom created a shadow market of compounded GLP-1s, fake labels, telehealth claims, dosing confusion, and patients who may not know what they are actually getting.

Why now

Regulatory warnings and investigations are converging on the same problem: patients cannot always tell what product they are receiving.

Overclaim risk
medium-high
Primary source
Trade news
Published
Jun 24, 2026
Read brief ->

Research map

View related studies

Research records connected to this topic through topic tags, source records, and timeline events.

Tier 1Government safety pagetopic context

FDA compounded ketamine warning

FDA warns patients and health care providers about potential risks associated with compounded ketamine products

Government safety page from 2023 in U.S. Food and Drug Administration, translated into key findings, limitations, and consumer relevance.

Why this appears: Shown as discovery context only because no accepted page-level relationship metadata was supplied.

U.S. Food and Drug Administration / 2023->

Useful source library entries

FDA clarifies policies for compounders as GLP-1 supply stabilizesHouston Chronicle: GLP-1 weight-loss boom and Empower Pharmacy investigationFDA: Concerns with Unapproved GLP-1 Drugs Used for Weight LossReuters: FDA letters to telehealth companies over compounded weight-loss drug claimsFDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting

Related topics

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No selling your information. Unsubscribe anytime.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.